A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases

Overview

Journal Front Neurosci

Date 2021 Oct 11

PMID 34630029

Citations 21

Authors

Jonathan M Fischell

Paul S Fishman

Affiliations

Soon will be listed here.

Abstract

Despite major advancements in gene therapy technologies, there are no approved gene therapies for diseases which predominantly effect the brain. Adeno-associated virus (AAV) vectors have emerged as the most effective delivery vector for gene therapy owing to their simplicity, wide spread transduction and low immunogenicity. Unfortunately, the blood-brain barrier (BBB) makes IV delivery of AAVs, to the brain highly inefficient. At IV doses capable of widespread expression in the brain, there is a significant risk of severe immune-mediated toxicity. Direct intracerebral injection of vectors is being attempted. However, this method is invasive, and only provides localized delivery for diseases known to afflict the brain globally. More advanced methods for AAV delivery will likely be required for safe and effective gene therapy to the brain. Each step in AAV delivery, including delivery route, BBB transduction, cellular tropism and transgene expression provide opportunities for innovative solutions to optimize delivery efficiency. Intra-arterial delivery with mannitol, focused ultrasound, optimized AAV capsid evolution with machine learning algorithms, synthetic promotors are all examples of advanced strategies which have been developed in pre-clinical models, yet none are being investigated in clinical trials. This manuscript seeks to review these technological advancements, and others, to improve AAV delivery to the brain, and to propose novel strategies to build upon this research. Ultimately, it is hoped that the optimization of AAV delivery will allow for the human translation of many gene therapies for neurodegenerative and other neurologic diseases.

Citing Articles

Glial Cell Reprogramming in Ischemic Stroke: A Review of Recent Advancements and Translational Challenges.

Gresita A, Hermann D, Boboc I, Doeppner T, Petcu E, Semida G Transl Stroke Res. 2025; .

PMID: 39904845 DOI: 10.1007/s12975-025-01331-7.

Current views on etiology, diagnosis, epidemiology and gene therapy of maturity onset diabetes in the young.

Dzhemileva L, Zakharova E, Goncharenko A, Vorontsova M, Rumyantsev S, Mokrysheva N Front Endocrinol (Lausanne). 2025; 15:1497298.

PMID: 39902162 PMC: 11788143. DOI: 10.3389/fendo.2024.1497298.

Advances and Challenges in Gene Therapy for Neurodegenerative Diseases: A Systematic Review.

Garcia-Gonzalez N, Goncalves-Sanchez J, Gomez-Nieto R, Goncalves-Estella J, Lopez D Int J Mol Sci. 2024; 25(23).

PMID: 39684197 PMC: 11640776. DOI: 10.3390/ijms252312485.

Benzoxazole-derivatives enhance progranulin expression and reverse the aberrant lysosomal proteome caused by GRN haploinsufficiency.

Tesla R, Guhl C, Werthmann G, Dixon D, Cenik B, Addepalli Y Nat Commun. 2024; 15(1):6125.

PMID: 39033178 PMC: 11271458. DOI: 10.1038/s41467-024-50076-8.

Gene replacement therapies for inherited disorders of neurotransmission: Current progress in succinic semialdehyde dehydrogenase deficiency.

Lee H, Tokatly Latzer I, Bertoldi M, Gao G, Pearl P, Sahin M J Inherit Metab Dis. 2024; 47(3):476-493.

PMID: 38581234 PMC: 11096052. DOI: 10.1002/jimd.12735.

References

Rosenberg J, Kaplitt M, De B, Chen A, Flagiello T, Salami C . AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. Hum Gene Ther Clin Dev. 2018; 29(1):24-47. PMC: 5870071. DOI: 10.1089/humc.2017.231. View

Tanguy Y, Biferi M, Besse A, Astord S, Cohen-Tannoudji M, Marais T . Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. Front Mol Neurosci. 2015; 8:36. PMC: 4516891. DOI: 10.3389/fnmol.2015.00036. View

Leinenga G, Gotz J . Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model. Sci Transl Med. 2015; 7(278):278ra33. DOI: 10.1126/scitranslmed.aaa2512. View

Kovacs Z, Tu T, Sundby M, Qureshi F, Lewis B, Jikaria N . MRI and histological evaluation of pulsed focused ultrasound and microbubbles treatment effects in the brain. Theranostics. 2018; 8(17):4837-4855. PMC: 6160777. DOI: 10.7150/thno.24512. View

Snyder B, Gray S, Quach E, Huang J, Leung C, Samulski R . Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther. 2011; 22(9):1129-35. DOI: 10.1089/hum.2011.008. View

Chu C, Jablonska A, Lesniak W, Thomas A, Lan X, Linville R . Optimization of osmotic blood-brain barrier opening to enable intravital microscopy studies on drug delivery in mouse cortex. J Control Release. 2019; 317:312-321. DOI: 10.1016/j.jconrel.2019.11.019. View

Samaranch L, Salegio E, San Sebastian W, Kells A, Foust K, Bringas J . Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther. 2011; 23(4):382-9. PMC: 3327605. DOI: 10.1089/hum.2011.200. View

Fugate J . Complications of Neurosurgery. Continuum (Minneap Minn). 2015; 21(5 Neurocritical Care):1425-44. DOI: 10.1212/CON.0000000000000227. View

Elmer B, Swanson K, Bangari D, Piepenhagen P, Roberts E, Taksir T . Gene delivery of a modified antibody to Aβ reduces progression of murine Alzheimer's disease. PLoS One. 2019; 14(12):e0226245. PMC: 6936806. DOI: 10.1371/journal.pone.0226245. View

10.

Samaranch L, Bringas J, Pivirotto P, San Sebastian W, Forsayeth J, Bankiewicz K . Cerebellomedullary Cistern Delivery for AAV-Based Gene Therapy: A Technical Note for Nonhuman Primates. Hum Gene Ther Methods. 2016; 27(1):13-6. PMC: 4761826. DOI: 10.1089/hgtb.2015.129. View

11.

Deverman B, Ravina B, Bankiewicz K, Paul S, Sah D . Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discov. 2018; 17(9):641-659. DOI: 10.1038/nrd.2018.110. View

12.

Koenig M . Cerebral Edema and Elevated Intracranial Pressure. Continuum (Minneap Minn). 2018; 24(6):1588-1602. DOI: 10.1212/CON.0000000000000665. View

13.

Hsu P, Wei K, Huang C, Wen C, Yen T, Liu C . Noninvasive and targeted gene delivery into the brain using microbubble-facilitated focused ultrasound. PLoS One. 2013; 8(2):e57682. PMC: 3584045. DOI: 10.1371/journal.pone.0057682. View

14.

Chu C, Liu G, Janowski M, Bulte J, Li S, Pearl M . Real-Time MRI Guidance for Reproducible Hyperosmolar Opening of the Blood-Brain Barrier in Mice. Front Neurol. 2018; 9:921. PMC: 6212512. DOI: 10.3389/fneur.2018.00921. View

15.

Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N . Adeno-Associated Virus-Based Gene Therapy for CNS Diseases. Hum Gene Ther. 2016; 27(7):478-96. PMC: 4960479. DOI: 10.1089/hum.2016.087. View

16.

Cavazzana-Calvo M, Fischer A . Gene therapy for severe combined immunodeficiency: are we there yet?. J Clin Invest. 2007; 117(6):1456-65. PMC: 1878528. DOI: 10.1172/JCI30953. View

17.

Hanlon K, Meltzer J, Buzhdygan T, Cheng M, Sena-Esteves M, Bennett R . Selection of an Efficient AAV Vector for Robust CNS Transgene Expression. Mol Ther Methods Clin Dev. 2019; 15:320-332. PMC: 6881693. DOI: 10.1016/j.omtm.2019.10.007. View

18.

Samaranch L, San Sebastian W, Kells A, Salegio E, Heller G, Bringas J . AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther. 2014; 22(2):329-337. PMC: 3918916. DOI: 10.1038/mt.2013.266. View

19.

Kovacs G . Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. Int J Mol Sci. 2016; 17(2). PMC: 4783923. DOI: 10.3390/ijms17020189. View

20.

Pearce M . Prion-like transmission of pathogenic protein aggregates in genetic models of neurodegenerative disease. Curr Opin Genet Dev. 2017; 44:149-155. DOI: 10.1016/j.gde.2017.03.011. View